Welcome – J. M. Llibre

Long-acting ARV formulations knocking on the door – Courtney V. Fletcher

2DR Debate: The “Pro” argument – Chloe Orkin

2DR Debate: In support of three drug regimens – Laura Waters

Top DDI in clinical practice: Still relevant? – Catia Marzolini

New drugs for unmet needs. A clinician’s view – Jürgen Rockstroh

Industry Round Table: ViiV – R&D Strategy. Where are we heading? – Jan van Lunzen

Industry Round Table: Gilead – HIV Pipeline – Devi SenGupta

Industry Round Table: MSD – HIV Research Update – Fernando A. Bognar

Industry Round Table: Janssen – ¿Where are we headed? – Eugenia Vispo

Industry Round Table: Thera Technologies – Vision for the Future – Brandon Cash

How to reduce HIV incidence in Europe – Teymur Noori

Jump Start ART: Is it still relevant to E.U.? – Jean-Jacques Parienti

What we have achieved in Africa so far? So close yet so far away – Francois Venter

PrEP and STIs – STIs and PrEP – Pep Coll

NASH: The next liver epidemic in HIV? – James Maurice

Clinical Cases Discussion: Fertile woman with pregnancy potential – Franco Maggiolo

Clinical Cases Discussion: Drug resistance testing in naive patients – Carlo F. Perno

Clinical Cases Discussion: Young MSM with perianal a ulcer – Adrià Curran

Clinical Cases Discussion: Aging – Ignacio Bernardino